Cardiovascular Risk Comparison between Expanded Hemodialysis using Theranova and On-line Hemodiafiltratio
- Conditions
- Diseases of the genitourinary system
- Registration Number
- KCT0003188
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Eighty patients undergoing thrice-weekly hemodialysis were randomly assigned to receive either HDx with a Theranova membrane (n = 43) or online-HDF (n = 37). 65 patients had completed the trial. The changes in baPWV and echocardiographic parameters did not differ between the two groups. The CAC scores remained stable in the online-HDF group, whereas an increasing trend was shown in the HDx group (P = 0.012). Other endpoints, including cardiovascular and all-cause mortalities, were similar between the two groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 80
1. Age = 18 years
2. Hemodialysis due to end-stage renal disease at least for 3 months
3. Informed consent
1. Perform on-line hemodialysis before enrollment
2. Hemodialysis done not by 3 times per week (e.g. 1 time per week)
3. Peritoneal dialysis together
4. Have a plant to receive kidney transplantation within 1 year
5. Multiple myeloma or monoclonal gammopathy
6. Aggravating cancer status with or without chemotherapy
7. Pregnant, nursing, or plan to be pregnant within 1 year
8. Subjects participating in other clinical trial
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pulse Wave Velocity, PWV
- Secondary Outcome Measures
Name Time Method Surrogate marker of cardiovascular disease risk (CT coronary calcium scoring, Transthoracic echocardiography);Blood biomarker of cardiovascular disease risk (BNP & NT-proBNP, High-sensitivity CRP, Troponin I & troponin T, IL-6);Patient-reported outcome